BTIG Downgrades EPIRUS Biopharmaceuticals (EPRS) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Wedbush Downgrades EPIRUS Biopharmaceuticals (EPRS) to Neutral
May 11, 2016 6:58 AM EDTWedbush downgraded EPIRUS Biopharmaceuticals (NASDAQ: EPRS) from Outperform to Neutral with a price target of $2.00 (from $11.00) as the company shifts its business model to focus on biosimilars for rare diseases.
Analyst Heather Behanna commented, "Epirus is shifting its business model to... More
EPIRUS Biopharma (EPRS) Will Reallocate Resources to Focus on BOW080, BOW070 Development
May 9, 2016 4:01 PM EDTEPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS) announced reprioritization of the companys pipeline to focus exclusively on developing biosimilars for the treatment of rare diseases. This includes reallocating the Companys resources to focus on the development of BOW080 (eculizumab; reference... More
